# Judy C. Boughey

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/judy-c-boughey/

## Facts

| Field | Value |
| --- | --- |
| Citations | 24,615 |
| Field | Breast Cancer Treatment Studies |
| h-index | 81 |
| i10-index | 336 |
| Last Known Institution | Mayo Clinic |
| OpenAlex ID | https://openalex.org/A5033544737 |
| ORCID iD | 0000-0003-3820-3228 |
| Works | 846 |

## Researcher papers

Showing 12 of 17.

- [Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer](https://scholariq.org/papers/sentinel-lymph-node-surgery-after-neoadjuvant-chemotherapy-in-patients-with-node/)
- [Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer](https://scholariq.org/papers/effect-of-pembrolizumab-plus-neoadjuvant-chemotherapy-on-pathologic-complete/)
- [Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer](https://scholariq.org/papers/adaptive-randomization-of-veliparib-carboplatin-treatment-in-breast-cancer/)
- [Adaptive Randomization of Neratinib in Early Breast Cancer](https://scholariq.org/papers/adaptive-randomization-of-neratinib-in-early-breast-cancer/)
- [Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0–T4, N1–N2) Who Receive Neoadjuvant Chemotherapy](https://scholariq.org/papers/identification-and-resection-of-clipped-node-decreases-the-false-negative-rate/)
- [Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer](https://scholariq.org/papers/tumor-biology-correlates-with-rates-of-breast-conserving-surgery-and-pathologic/)
- [Trends in Mastectomy Rates at the Mayo Clinic Rochester: Effect of Surgical Year and Preoperative Magnetic Resonance Imaging](https://scholariq.org/papers/trends-in-mastectomy-rates-at-the-mayo-clinic-rochester-effect-of-surgical-year/)
- [w4200350191](https://scholariq.org/papers/w4200350191/)
- [Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons](https://scholariq.org/papers/consensus-guidelines-on-genetic-testing-for-hereditary-breast-cancer-from-the/)
- [Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial](https://scholariq.org/papers/durvalumab-with-olaparib-and-paclitaxel-for-high-risk-her2-negative-stage-ii-iii/)
- [Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer](https://scholariq.org/papers/association-of-event-free-and-distant-recurrence-free-survival-with-individual/)
- [DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine](https://scholariq.org/papers/dna-methyltransferase-expression-in-triple-negative-breast-cancer-predicts/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Breast Lesions and Carcinomas](https://scholariq.org/topics/breast-lesions-and-carcinomas/)
- [Breast Implant and Reconstruction](https://scholariq.org/topics/breast-implant-and-reconstruction/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Researcher university

- [Mayo Clinic](https://scholariq.org/institutions/mayo-clinic/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.